Supriya Lifescience Ltd (SUPRIYA.BO)
Supriya Lifescience Ltd operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Mumbai, MH, IN. The stock last traded at $792.20, down 2.59% on the session, giving a market capitalisation of $63.75B. Its beta of 0.67 implies it has historically moved less than the broad market.
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Supriya Lifescience Ltd is most often compared with the following Healthcare names: